Amsterdam, The Netherlands – 16 November 2017 – It is with great pleasure that LSP – the specialist European healthcare investment firm – announces that its portfolio company Orphazyme was successfully listed on the Nasdaq Copenhagen, Denmark, raising approximately €80 million after the pricing of DKK 80 per share, corresponding to a post-money market cap of DKK 1,594 million (€214 million). The IPO was several times oversubscribed. The shares are trading under the (permanent) ticker symbol “ORPHA DC Equity”.
LSP, together with the ALS Investment Fund, financed Orphazyme in March 2017 and joined the company’s Series B extension round. Martijn Kleijwegt, Managing Partner at LSP and Board Member at Orphazyme, comments: “LSP and the ALS investment fund believed that this company was at a time when the company is pushing the boundaries and bringing its technology to a wider range of diseases that have devastating consequences for the sufferers and their loved ones. This has now, only 8 months later, resulted in Orphazyme’s IPO being one of the most successful IPOs for Biotech in Europe with 80M€ raised before the 15% overallotment option. An excellent achievement for the company, proving Orphazyme’s leading position in the rare disease space.”
About Orphazyme ApS
Orphazyme ApS is a Danish biotech company that develops paradigm-changing medicines for the treatment of protein misfolding diseases with well-characterised mechanisms of disease. The lead programme is in development as a treatment for the lysosomal storage disease Niemann-Pick disease type C. This is one of a family ~50 debilitating genetic disorders that often affect children, most of whom are currently untreatable. For more information, please visit www.orphazyme.com.
LSP is an independent European investment firm, providing financing for private and public life sciences companies. LSP’s mission is to connect investors to inventors, focusing on unmet medical needs. Since the late 1980s, LSP’s management has invested in about 100 innovative enterprises, many of which have grown to become leaders of the global life sciences industry. With over €1 billion of investment capital raised to date and offices in Amsterdam, Munich and Boston, LSP is one of Europe’s leading life sciences investors. For more information, please visit lspvc.com.
About ALS Investment Fund
The ALS Investment Fund supports and finances biotech companies that develop drugs and diagnostics for Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease). The Fund was initiated by 3 Dutch ALS patients and is supported by a top-tier European VC firm, Life Sciences Partners. The ALS Investment Fund invests globally, but focuses on Europe and the US. The fund brings depth of disease-specific knowledge and a deep network in the space. More information is available at www.alsinvestmentfund.com.
Martijn Kleijwegt, Managing Partner LSP